NETRI is excited to announce its recent milestone achievement of raising $5,000,000 in new funding, a testament to the company’s pioneering spirit and the transformative impact of its technology on neurological research. As a leading technology-enabling company, NETRI is at the forefront of providing human cell-based smart assays designed for high throughput preclinical data acquisition within the neurological Pharma and Cosmetics industries. This significant investment not only acknowledges the innovative strength of NETRI’s organ-on-chip solutions and interoperable in vitro models but also fuels its mission to accelerate drug discovery and enhance preclinical trial efficiency.
The raised funds will be strategically directed toward expanding NETRI’s state-of-the-art research facilities, developing more sophisticated assay systems, and scaling up production capacity to meet rising market demands. With these enhanced capabilities, the company is set to offer deeper insights into complex neural connectivity by replicating in vivo conditions with remarkable precision. This advancement will empower pharmaceutical and cosmetic partners to streamline their research processes, reduce reliance on conventional animal models, and gain more reliable data during early-stage development.
Furthermore, the infusion of capital will accelerate NETRI’s ongoing collaborations with key industry players, fostering an ecosystem of innovation that bridges the gap between preclinical research and clinical success. By investing in cutting-edge technology and expanding its operational capacity, NETRI is poised to make a lasting impact on drug discovery and safety assessments. This funding announcement marks a turning point that not only supports the company’s growth trajectory but also reinforces its commitment to advancing healthcare and cosmetic sciences through unparalleled, human-relevant models.
